Radius' osteoporosis treatment comes through in Phase III; Biodel gets out from under FDA hold;

@FierceBiotech: Lilly upgrades its NYC research hub, adding 50 jobs in an immuno-oncology push. News | Follow @FierceBiotech

@JohnCFierce: How many big swings and misses does John Lechleiter get at $LLY? | Follow @JohnCFierce

@DamianFierce: Tired of writing about $LLY today so here's a hypoglycemia deal you can read about yourself. Press release | Follow @DamianFierce

> Radius Health's ($RDUS) in-development osteoporosis treatment reduced the rate of major fractures by 70% compared with placebo in a Phase III trial, the company said. News

> The FDA removed a partial clinical hold on Biodel's ($BIOD) Type 2 diabetes treatment, allowing the company to move forward with a Phase II study. Item

> Spark Therapeutics ($ONCE) added more positive results to its previously disclosed Phase III data, noting that its gene therapy for retinal disease improved functional function and light sensitivity. More

Medical Device News

@FierceMedDev: ICYMI Friday: Procyrion raises $10M to get minimally invasive mini heart pump in the clinic. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI last week from #AdvaMed15: CMS has 30 people to evaluate 30,000 diagnostic tests, but more FDA oversight is likely. More | Follow @VarunSaxena2

@EmilyWFierce: The latest from Advera Health Analytics on Alzheimer's drug safety. ICYMI from FiercePharma | Follow @EmilyWFierce

> NuVasive gets FDA blessing for spinal cord surgical device. Report

> Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. More

> Neurosurgeons hope brain implants can be used to treat array of mental disorders. Article

Pharma News

@FiercePharma: Study: Elephants rarely get cancer--and that could boost human oncology research. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sanofi's Kansas City, MO, plant back on the block as its August 2016 closing looms. Story | Follow @EricPFierce

@CarlyHFierce: Backlash rages on over Purdue's pediatric OxyContin approval. Story | Follow @CarlyHFierce

> BMS' Opdivo gets a jump on Keytruda with another early FDA approval. Article

> Price hikes aren't always sustainable: Just ask Mallinckrodt about Ofirmev. More

> Takeda keeps Actos settlement ball rolling with two new resolutions. Report

Animal Health News

> Study: Elephants rarely get cancer--and that could boost human oncology research. More

> Ceva urges mass vaccination against bird flu at global animal-health gathering. Story

> FDA seeks comments on potential scheduling change for ketamine. Item

> California sets strictest U.S. standards for antibiotics use in livestock. Article

> CalTech team creates one-time contraceptive vaccine for feral animals. Report

Biotech IT News

> NIH gives UCSF $10M to build mobile data collection platform. News

> GSK finds 21M mentions of its drugs in trawl of social media. Report

> ResearchKit-enabled project sets out to track real-world effectiveness of hep C drugs. Story

> UBiome taps Apple ecosystem to broaden microbiome data-gathering drive. Article

> Is Google a competitor or partner to Big Pharma? Roche's CEO doesn't know, yet. More

Pharma Marketing News

> Baxalta joins biosim makers eyeing a piece of AbbVie's Humira. More

> Biogen's top commercial exec leaves amid Tecfidera sales trouble. Report

> Roche leads the pack at ECTRIMS with standout data on new MS drug. Item

> Bill seeks to add nurse practitioners, PAs to Sunshine Act reporting. Story

> Pharma's digital desires thwarted by clunky organizations, lack of skilled employees. Article

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.